Long-Term Safety and Efficacy of HB0034 in Subjects With Generalized Pustular Psoriasis

NCT06477536 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

RECRUITING

Status

33

Enrollment

INDUSTRY

Sponsor class

Conditions

Generalized Pustular Psoriasis

Interventions

DRUG: HB0034

Sponsor

Shanghai Huaota Biopharmaceutical Co., Ltd.